Skip to main content
Clinical Trials/NCT04751162
NCT04751162
Completed
Not Applicable

An Observational Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.

Hoffmann-La Roche10 sites in 1 country71 target enrollmentFebruary 18, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Sponsor
Hoffmann-La Roche
Enrollment
71
Locations
10
Primary Endpoint
ECOG-PS assessment of LC participants measured by data collected through wearable and a mobile application
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The current research is a non-interventional (NIS) study seeking to support objective Performance Status (PS) assessments in the particular context of metastatic NSCLC adult patients. To do so, the study comprises two phases. Phase I addresses a feasibility mixed-methods (quantitative-qualitative) approach. It primarily focuses on examining perceived technology usability in a limited sample of participants and feasibility of translating the actigraph data into PS scores (focus expert group). Phase II focuses on to primarily examine associations between technology collected data and ECOG-PS in a larger sample of participants.

Registry
clinicaltrials.gov
Start Date
February 18, 2021
End Date
May 1, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

ECOG-PS assessment of LC participants measured by data collected through wearable and a mobile application

Time Frame: From baseline up to 9 months

ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)

Usability of the wearable device perceived by clinical investigators

Time Frame: From baseline up to 9 months

System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.

Usability of the wearable device perceived by LC participants

Time Frame: From baseline up to 9 months

System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.

Usability of the mobile application perceived by clinical investigators

Time Frame: From baseline up to 9 months

System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.

ECOG-PS assessment of LC participants measured by clinical investigators

Time Frame: From baseline up to 9 months

ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)

Usability of the mobile application perceived by LC participants

Time Frame: From baseline up to 9 months

System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.

Secondary Outcomes

  • Sensitivity to changes in ECOG-PS over time measured by wearable and mobile application(From baseline up to 9 months)
  • Sensitivity to changes in ECOG-PS over time measured by clinical investigators(From baseline up to 9 months)

Study Sites (10)

Loading locations...

Similar Trials